Literature DB >> 12628059

Diagnosis and Treatment of Nonconvulsive Status Epilepticus in an Intensive Care Unit Setting.

Stephan J. Rüegg1, Marc A. Dichter.   

Abstract

Nonconvulsive status epilepticus (NCSE) in adults is a heterogeneous epileptic emergency and includes absence status (AS), complex-partial status epilepticus (CPSE), and the status epilepticus of epileptic encephalopathy (SEEE). The latter seems to be strikingly frequent among patients in intensive care units (ICU). Diagnosis of NCSE is difficult, but has to be made quickly. It relies on clinical signs and a confirmation electroencephalography (EEG). According to the different etiologies and outcomes of AS, CPSE, and SEEE, treatment has to be individually adapted, but needs to follow some basic principles--treatment should take place in the ICU and be monitored by continuous EEG. With a few exceptions, the first drug is an intravenous benzodiazepine, mainly lorazepam. Intravenous fosphenytoin or phenytoin or valproate may follow next. If some forms of NCSE are resistant to first- and second-line treatments, single or combinations of anesthetics and enteral antiepileptic drugs (AEDs) may be added. This opinion is not evidence-based, and randomized controlled prospective trials to evaluate optimal treatment of NCSE are of first priority.

Entities:  

Year:  2003        PMID: 12628059     DOI: 10.1007/s11940-003-0001-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  77 in total

1.  Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department.

Authors:  D R Touchette; D H Rhoney
Journal:  Pharmacotherapy       Date:  2000-08       Impact factor: 4.705

Review 2.  Management of status epilepticus.

Authors:  M J Aminoff
Journal:  Can J Neurol Sci       Date:  1998-02       Impact factor: 2.104

Review 3.  Levetiracetam: a different approach to the pharmacotherapy of epilepsy.

Authors:  Timothy E Welty; Barry E Gidal; David M Ficker; Michael D Privitera
Journal:  Ann Pharmacother       Date:  2002-02       Impact factor: 3.154

Review 4.  Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.

Authors:  J C DeToledo; R E Ramsay
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

5.  Nonconvulsive status epilepticus of frontal origin.

Authors:  P Thomas; B Zifkin; O Migneco; C Lebrun; J Darcourt; F Andermann
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

6.  Treatment of refractory partial status epilepticus with multiple subpial transection: case report.

Authors:  C H D'Giano; M Del C García ; H Pomata; A L Rabinowicz
Journal:  Seizure       Date:  2001-07       Impact factor: 3.184

Review 7.  Evidence against permanent neurologic damage from nonconvulsive status epilepticus.

Authors:  F W Drislane
Journal:  J Clin Neurophysiol       Date:  1999-07       Impact factor: 2.177

Review 8.  Assessing the outcomes in patients with nonconvulsive status epilepticus: nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity.

Authors:  P W Kaplan
Journal:  J Clin Neurophysiol       Date:  1999-07       Impact factor: 2.177

Review 9.  Status epilepticus in older patients: epidemiology and treatment options.

Authors:  E J Waterhouse; R J DeLorenzo
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 10.  Electroclinical features of status epilepticus.

Authors:  D M Treiman
Journal:  J Clin Neurophysiol       Date:  1995-07       Impact factor: 2.177

View more
  2 in total

1.  ECoG studies of valproate, carbamazepine and halothane in frontal-lobe epilepsy induced by head injury in the rat.

Authors:  Clifford L Eastman; Derek R Verley; Jason S Fender; Nancy R Temkin; Raimondo D'Ambrosio
Journal:  Exp Neurol       Date:  2010-04-24       Impact factor: 5.330

2.  Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes.

Authors:  Andrew Thomson
Journal:  Core Evid       Date:  2005-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.